<DOC>
	<DOCNO>NCT00454103</DOCNO>
	<brief_summary>The improvement conventional image technique lead increased detection rate different adrenal tumor . Since tumor belong variety entity therapeutic consequence also show considerable variation . In order definitely determine type tumor , invasive procedure like CT guide biopsy often require , could avoid tumor specific image method . The presently available scintigraphic procedure either time consume lead high radiation exposure technically demand . The steroidogenic enzyme CYP11B1 ( 11ß-hydroxylase ) CYP11B2 ( aldosterone synthase ) express exclusively adrenal cortex therefore represent suitable target specific image technique . In project evaluate 123I-Iodometomidate bind CYP11B enzymes radiotracer adrenal scintigraphy .</brief_summary>
	<brief_title>Evaluation 123I-Iodometomidate Adrenal Scintigraphy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Adrenal Gland Neoplasms</mesh_term>
	<mesh_term>Etomidate</mesh_term>
	<criteria>1 . Adrenal tumor see CT MRTscan diameter least 2 cm patient adrenocortical carcinoma suspect metastasis local recurrence patient primary hyperaldosteronismus adrenal tumour &gt; 1 cm 2 . Hormonal work adrenal tumor accord ENS @ T ( European network study adrenal tumour ) criteria 3 . Age ≥ 30 Jahre 4 . Effective contraception ( pearl index &lt; 1 % ) 5 . Written inform consent 1 . Pregnancy breast feed 2 . Renal insufficiency ( serum creatinine &gt; 2,0 mg/dl MDRD &lt; 60 ml/min ) 3 . Known allergy etomidate constituent test drug</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>adrenocortical carcinoma ( ACC )</keyword>
	<keyword>adrenal tumor</keyword>
	<keyword>metastastic adrenocortical carcinoma</keyword>
</DOC>